Drugs / REGN6490
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04616079 | Nov 2020 → Jun 2021 | — | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04616105 | Nov 2020 → May 2021 | — | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN6490 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04616105 ↗ |
| Route | Intravenous | “intravenous (IV)” NCT04616079 ↗ |